TENX conference cites levosimendan biological effects in sicker patients
TradingView News reports a TENX conference highlighted new levosimendan biological effects, especially in sicker patients, despite missing the primary endpoint after enrolling too many healthier subjects. Future trials will target higher disease-burden patients.
The conference highlighted new data showing strong biological effects of levosimendan, especially in sicker patients, despite missing the primary endpoint because too many healthier subjects were enrolled. Future trials will focus on enrolling patients with higher disease burden, with safety data suppor…